Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
Status:
Terminated
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, double-blind, placebo-controlled, parallel-group study of
dexmedetomidine versus placebo, with lorazepam rescue, for the management of severe alcohol
withdrawal syndrome (AWS) and alcohol withdrawal delirium (AWD) in critically ill adults.
The investigators hypothesize that the integration of dexmedetomidine (Precedex®) with usual
therapy for the management of severe alcohol withdrawal syndrome (AWS) and alcohol withdrawal
delirium/delirium tremens (AWD) in critically ill adult patients will reduce the time to
resolution of AWS/AWD, increase the number of delirium-free and ventilator-free days in the
first 28 days of hospitalization, reduce the length of ICU and hospital stays, and improve
neurocognitive and quality of life scores on hospital discharge.